Log in

NASDAQ:STRO - Sutro Biopharma Stock Price, Forecast & News

-0.07 (-0.63 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
Now: $11.13
50-Day Range
MA: $10.60
52-Week Range
Now: $11.13
Volume34,949 shs
Average Volume49,446 shs
Market Capitalization$256.99 million
P/E RatioN/A
Dividend YieldN/A
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:STRO



Sales & Book Value

Annual Sales$38.42 million
Book Value($6.58) per share


Net Income$-35,320,000.00


Market Cap$256.99 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive STRO News and Ratings via Email

Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma Inc (NASDAQ:STRO) announced its quarterly earnings results on Friday, November, 8th. The company reported ($0.56) EPS for the quarter, beating the Zacks' consensus estimate of ($0.65) by $0.09. The business earned $12.28 million during the quarter, compared to the consensus estimate of $8.88 million. View Sutro Biopharma's Earnings History.

When is Sutro Biopharma's next earnings date?

Sutro Biopharma is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Sutro Biopharma.

What price target have analysts set for STRO?

6 Wall Street analysts have issued 1 year price objectives for Sutro Biopharma's stock. Their forecasts range from $16.00 to $22.00. On average, they anticipate Sutro Biopharma's share price to reach $19.40 in the next year. This suggests a possible upside of 74.3% from the stock's current price. View Analyst Price Targets for Sutro Biopharma.

What is the consensus analysts' recommendation for Sutro Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sutro Biopharma.

What are Wall Street analysts saying about Sutro Biopharma stock?

Here are some recent quotes from research analysts about Sutro Biopharma stock:
  • 1. According to Zacks Investment Research, "Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. " (8/17/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Sutro is derived from a 13-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.60, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.3%, and tax rate of 15% beginning in FY 2029. Until clarity on Sutro’s collaboration with Celgene and Merck crystallizes, our $18 price target remains leveraged on the outcome of STRO-002’s safety and efficacy outcome, which represents approximately 67% of our rNPV of $12 per share." (5/7/2019)

Has Sutro Biopharma been receiving favorable news coverage?

News articles about STRO stock have trended positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sutro Biopharma earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Sutro Biopharma.

Are investors shorting Sutro Biopharma?

Sutro Biopharma saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 152,900 shares, an increase of 6.3% from the November 14th total of 143,900 shares. Based on an average daily volume of 52,900 shares, the days-to-cover ratio is currently 2.9 days. Approximately 1.8% of the shares of the company are sold short. View Sutro Biopharma's Current Options Chain.

Who are some of Sutro Biopharma's key competitors?

What other stocks do shareholders of Sutro Biopharma own?

Who are Sutro Biopharma's key executives?

Sutro Biopharma's management team includes the folowing people:
  • Mr. William J. Newell, CEO & Director (Age 61)
  • Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)
  • Dr. Arturo M. Molina, Chief Medical Officer (Age 60)
  • Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory Board
  • Mr. Edward C. Albini, CFO & Sec. (Age 61)

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (2.27%), State Street Corp (0.67%), Millennium Management LLC (0.11%), Squarepoint Ops LLC (0.09%), Rhumbline Advisers (0.06%) and Barclays PLC (0.06%). Company insiders that own Sutro Biopharma stock include Daniel H Petree, Merck & Co, Inc and Trevor Hallam. View Institutional Ownership Trends for Sutro Biopharma.

Which institutional investors are selling Sutro Biopharma stock?

STRO stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC and SG Americas Securities LLC. View Insider Buying and Selling for Sutro Biopharma.

Which institutional investors are buying Sutro Biopharma stock?

STRO stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, State Street Corp, Barclays PLC and Rhumbline Advisers. View Insider Buying and Selling for Sutro Biopharma.

How do I buy shares of Sutro Biopharma?

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $11.13.

How big of a company is Sutro Biopharma?

Sutro Biopharma has a market capitalization of $256.99 million and generates $38.42 million in revenue each year. The company earns $-35,320,000.00 in net income (profit) each year or ($6.13) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe.View Additional Information About Sutro Biopharma.

What is Sutro Biopharma's official website?

The official website for Sutro Biopharma is http://www.sutrobio.com/.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412.

MarketBeat Community Rating for Sutro Biopharma (NASDAQ STRO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote "Outperform" if you believe STRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel